Assessment of Health State Utilities for Invasive Pneumococcal Disease, Pneumonia, and Acute Otitis Media in Young Children
Author(s)
Matza L1, Howell TA2, Chun B3, Hetherington L4, White M3, Weiss T3, Huang M3, Rowen D5, Tan T6, Feemster K3, Nozad B7, Kelly M8, Mohanty S3
1Evidera, Bethesda, MD, USA, 2Patient-Centered Research, Evidera, Bethesda, MD, USA, 3Merck Research Laboratories, Merck & Co, Inc., Rahway, NJ, USA, 4Patient-Centered Research, Evidera, London, LON, UK, 5University of Sheffield, Sheffield, South Yorkshire, UK, 6Feinberg School of Medicine, Northwestern University, Evanston, IL, USA, 7Imperial College London, London, England, UK, 8Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
Presentation Documents
OBJECTIVES: New vaccines have been developed for pneumococcal disease in children. Cost-utility analyses (CUAs) are often used to examine the value of new vaccines and require health state utilities as inputs. However, existing utilities for pneumococcal infections in children are limited. The purpose of this study was to estimate health state utilities associated with Streptococcus pneumoniae infections in children.
METHODS: Six health state vignettes depicting S. pneumoniae infections were drafted based on published literature and clinician interviews. To address methodological challenges in estimating utilities for temporary infections in children aged five and under, several time trade-off approaches were explored in a pilot study (N=28), the results of which informed selection of a time trade-off frame for the utility elicitation study. Health states were valued in time trade-off interviews (10-year time horizon, with infections repeated annually) with general population respondents from two UK locations.
RESULTS: A total of 208 participants completed interviews (51.9% female; mean (SD) age = 41.0 (14.9) years). Mean (SD) utilities were 0.902 (0.092) for pneumonia requiring hospitalization, 0.901 (0.087) for bacteremia, 0.894 (0.103) for recurrent acute otitis media (AOM), 0.882 (0.107) for recurrent AOM treated with pressure equalization tubes, 0.878 (0.109) for bacteremic pneumonia, and 0.809 (0.145) for meningitis. Given these health states described temporary infections occurring for several weeks each year with the child in full health for the remainder of the year, these values can be used to calculate quality-adjusted life year (QALY) decrements for use in modelling.
CONCLUSIONS: Lower health state utilities were associated with health states that had longer follow-up/treatment periods, required more invasive treatments/tests, and described infections that were perceived as more severe. Utilities from this study can be used in models examining cost-effectiveness of pneumococcal treatments or vaccines. These results have implications for future research estimating utilities associated with temporary pediatric conditions.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR157
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
Pediatrics, Vaccines